TORONTO, June 8 /PRNewswire/ - Trillium Therapeutics Inc. (TTI) today
announced that Dr. Marc Feldmann, a Professor at Imperial College London and
Head of the Kennedy Institute of Rheumatology Division, has agreed to join the
company's Scientific Advisory Board (SAB). Dr. Feldmann is welcomed to the
board by fellow members Drs. Mohamed Sayegh, Vijay Kuchroo, Brian Barber and
"Marc Feldmann is a pioneer in cytokine research and his work in the TNF
field is benefiting an ever increasing number of patients with autoimmune
disorders", commented Dr. Niclas Stiernholm, TTI's Chief Executive Officer.
"His experience and knowledge will provide us with an invaluable resource as
we advance both our CD200 development candidate and our new cytokine
antagonist program towards the clinic."
Dr. Marc Feldmann, Head of Kennedy Institute of Rheumatology Division at
the Imperial College London, is a leader in the field of TNF research and his
work has paved the way for today's blockbuster TNF-blocking drugs, which are
now used in a variety of autoimmune disorders. He has authored over 600
scientific articles, has written and edited several books and serves on the
editorial boards of a variety of scientific journals. Dr. Feldmann is the
recipient of many awards, including the 2000 Crafoord Prize of the Royal
Swedish Academy and 2003 Albert Lasker Clinical Research Award. He is an
inventor on numerous patents and is the founder of the 2001 start-up company,
Trillium Therapeutics Inc. is a privately held Research and Development
company that specializes in the development of innovative therapies that
restore balance to the immune system in conditions associated with aberrant
and harmful immune responses. These include autoimmune and inflammatory
disorders, graft rejection, cancer and viral hepatitis. The Company identifies
therapeutic candidates with promising preclinical profiles and advances these
into clinical testing, with the primary objective of demonstrating safety and
efficacy in humans. TTI currently has three development programs, one based on
the CD200 immunoregulatory protein and its receptor, a second targeting the
novel pro-thrombinase Fgl2, and a third that focuses on cytokine receptor
antagonists. TTI has a broad network of external R&D collaborations, including
several with major pharmaceutical and biotechnology companies.
SOURCE Trillium Therapeutics Inc.